Formulation: A crystalline solid

Purity: ≥99%

Formulation: 50 mM HEPES, pH 8.0, with 300 mM sodium chloride, and 10% glycerol

Purity: ≥90% estimated by SDS-PAGE

• C6orf150
• 2’3’-cGAMP Synthase
• cGAMP Synthase
• h-cGAS
• Cyclic GMP-AMP Synthase
• EC: 2.7.7.86
• Mab-21 domain containing protein 1
• MB21D1

Formulation: A liquid

Purity: ≥98%

• 5,5-Dimethyl-1-Pyrroline-N-Oxide

Formulation: A crystalline solid

Purity: ≥98%

• BocMPO

Formulation: A crystalline solid

Purity: ≥95%

Formulation: A 25 mg/ml solution in ethanol

Purity: ≥95%

• 5-(Ethoxycarbonyl)-5-methyl-1-Pyrroline-N-Oxide

Formulation: A crystalline solid

Purity: ≥95%

• 4-hydroxy TEMPO

Formulation: A 1 mg/ml solution in ethanol

Purity: ≥95%

• 12-DSA

Formulation: A crystalline solid

Purity: ≥98%

• 4-oxo-TEMPO
• Triacetoneamine nitroxide

Formulation: 50 mM HEPES, pH 8.0, 150 mM sodium chloride

Purity: ≥90% as estimated by SDS-PAGE

• Heme Oxygenase 2 Protein
• HMOX2

Formulation: A solid

Purity: ≥95%

• C16-amido TEMPO

Formulation: A solid

Purity: ≥98%

• M₄PO
• NSC 78027
• 3,3,5,5-Tetramethyl-1-pyrroline N-oxide

Formulation: A solid

Purity: ≥95%

• NSC 239127

Formulation: A solid

Purity: ≥98%

• 2,2’-Pyridylisatogen tosylate